Video

Adjuvant Strategies in Early-Stage HER2+ Breast Cancer

Transcript:

Related Videos
Alec Watson, MD
Sagar D. Sardesai, MBBS
DB-12
Balazs Halmos, MD
Balazs Halmos, MD
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Stephanie Graff, MD, and Chandler Park, FACP
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Related Content
Colorectal Cancer | stock.adobe.com
December 23rd 2024

Nivolumab Plus Ipilimumab Wins European Approval for MSI-H/dMMR mCRC

MedNews Week
December 12th 2024

Delve Into Data With Amivantamab Plus Lazertinib in EGFR-Mutated NSCLC: With Chandler Park, MD; and Stephen Liu, MD

Lung cancer, Image credit: Axel Kock – stock.adobe.com
December 23rd 2024

Nivolumab/CCRT Followed by Nivolumab/Ipilimumab Misses PFS End Point in Select Stage III NSCLC

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD
October 30th 2024

Ongoing Research Advances Equity and Precision Oncology Through Tissue-Agnostic Therapies: With Chandler Park, MD, and Vivek Subbiah, MD

OncLive's OncFive: The Top 5 Oncology Articles of the Week
December 21st 2024

The OncFive: Top Oncology Articles for the Week of 12/15

Non–Small Cell Lung cancer | Image Credit: © Axel Kock – stock.adobe.com
December 21st 2024

Perioperative Pembrolizumab Regimen Upholds Survival Benefit in Resectable NSCLC